nach oben

Erschienen in:

01.01.2011 | Original paper

Complementary approaches to assessing risk factors for interval breast cancer

verfasst von: Jan T. Lowery, Tim Byers, John E. Hokanson, John Kittelson, John Lewin, Betsy Risendal, Meenakshi Singh, Judy Mouchawar

Erschienen in: Cancer Causes & Control | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Objective

To examine risk factors for interval breast cancer among women screened in a population-based mammography program.

Methods

Risk for interval cancer was assessed in terms of both the incidence per 10,000 negative screens and the proportion of all breast cancers diagnosed among screened women. Interval (N = 557) and screen-detected cancers (N = 1,545) were identified among 208,667 women receiving mammography in Colorado (1994–2001). Logistic regression was used to assess independent effects of multiple factors.

Results

Overall risk of interval cancer was 29.5/10,000 women screened. Incidence was higher in women >50 years (OR: 2.28, 1.86–2.80), with family history (OR: 2.23, 1.85–2.70), with dense breasts (OR: 3.84, 2.76–5.35), and using hormones (OR: 1.54, 1.20–1.97). Hispanics had lower incidence than Whites (OR: 0.52, 0.34–0.81). Interval cancers represented 26% of all cancers diagnosed. This proportion was higher in women <50 (OR: 1.41, 1.09–1.82) and in women with dense breasts (OR: 2.95, 1.94–4.48).

Conclusions

Incidence of interval cancer increases with age, breast density, hormone use, and family history. Attempts to reduce occurrence of these cancers through more sensitive and/or intensive screening should focus on these subgroups. The disproportionate number of interval cancers associated with young age and dense breasts suggests these cancers result from both rapid growth and difficulties in detection.

Porter PL, El-Bastawissi AY, Mandelson MT et al (1999) Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 91(23):2020–2028CrossRefPubMed

Gilliland FD, Joste N, Stauber PM et al (2000) Biologic characteristics of interval and screen-detected cancers. J Natl Cancer Inst 92(9):743–749CrossRefPubMed

Crosier M, Scott D, Wilson RG, Griffiths CD, May FE, Westley BR (2001) High expression of the trefoil protein TFF1 in interval breast cancers. Am J Pathol 159(1):215–221PubMed

Raja MA, Hubbard A, Salman AR (2001) Interval breast cancer: is it a different type of breast cancer? Breast 10(2):100–108CrossRefPubMed

Crane CE, Luke CG, Rogers JM, Playford PE, Roder DM (2002) An analysis of factors associated with interval as opposed to screen-detected breast cancers, including hormone therapy and mammographic density. Breast 11(2):131–136CrossRefPubMed

Burrell HC, Sibbering DM, Wilson A et al (1996) Screening interval cancers: mammographic features and prognosis factors. Radiology 199(3):811–817PubMed

Klemi PJ, Toikkanen S, Rasanen O, Parvinen I, Joensuu H (1997) Mammography screening interval and the frequency of interval cancers in a population-based screening. Br J Cancer 75(5):762–766PubMed

Schroen AA, Wobbes T, van der Sluis RF (1996) Interval carcinomas of the breast: a group with intermediate outcome. J Surg Oncol 63(3):141–144CrossRefPubMed

Mandelson MT, Oestreicher N, Porter PL (2000) Breast density as a predictor of mammographic detection: comparison of interval and screen-detected cancers. J Natl Cancer Inst 92(13):1081–1087CrossRefPubMed

10.

Carney PA, Migliorettty DL, Yankaskas BC et al (2003) Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med 138:168–175PubMed

11.

Wang H, Bjurstam N, Bjorndal H et al (2001) Interval cancers in the Norwegian Breast Cancer Screening Program: frequency, characteristics and use of HRT. Int J Cancer 94:594–598CrossRefPubMed

12.

Brekelmans CT, Peeters PH, Faber JA, Duerenberg JJ, Collette HJ (1994) The epidemiologic profile of women with an interval cancer in the DOM screening programme. Breast Cancer Res Treat 30(3):223–232CrossRefPubMed

13.

Kerlikowske K, Grady D, Barclay J, Sickles EA, Ernster V (1996) Effect of age, breast density, and family history on the sensitivity of first screening mammography. JAMA 276:33–38CrossRefPubMed

14.

Kavanagh A, Mitchell H, Giles G (2000) Hormone replacement therapy and the accuracy of mammographic screening. Lancet 355:270–274CrossRefPubMed

15.

Nixon RM, Pharoah P, Tabar L et al (1999) Mammographic screening in women with a family history of breast cancer: some results from the Swedish two-county trial. Rev Epidemiol Sante Publique 48:325–333

16.

Kerlikowske K, Carner PA, Geller B et al (2000) Performance of screening mammography among women with and without a first-degree relative with breast cancer. Ann Intern Med 133:855–863PubMed

17.

Halapy E, Chiarelli AM, Klar N, Knight JA (2005) Accuracy of breast screening among women with and without a family history of breast and/or ovarian cancer. Breast Ca Rsch Treat 90:299–305CrossRef

18.

Surveillance, Epidemiology and End Results (SEER) (2004). National Cancer Institute, U.S. National Institutes of Health

19.

Elledge RM, Clark GM, Chamness GC, Osborne CK (1994) Tumor biologic factors and breast cancer prognosis among White, Hispanic and Black women in the United States. J Natl Cancer Inst 86(9):705–712CrossRefPubMed

20.

Jones BA, Kasl SV, Curnen MG, Owens PH, Dubrow R (1995) Can mammography screening explain the race difference in stage at diagnosis of breast cancer? Cancer 75(8):2103–2113CrossRefPubMed

21.

Hunter CP, Redmond CK, Chen VW et al (1993) Breast cancer: factors associated with stage at diagnosis in black and white women. Black/White Cancer Survival Study Group. J Natl Cancer Inst 85(14):1129–1137CrossRefPubMed

22.

Jacobellis J, Cutter G (2002) Mammography screening and differences in stage of disease by race/ethnicity. Am J Public Health 92(7):1144–1150CrossRefPubMed

23.

Nixon AJ, Neeuberg D, Hayes DF (1994) Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol 12:888–894PubMed

24.

Eerola H, Heikkila P, Tamminen A, Aittomaki K, Blomqvist C, Nevanlinna H (2005) Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res 7(1):R93–R100CrossRefPubMed

25.

Phillips KA, Nichol K, Ozcelik H et al (1999) Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations. JNCI 91:469–473PubMed

26.

U.S. Census Bureau, Population Division, 2002

27.

Hofvind S, Moller B, Thoresen S, Ursin G (2006) Use of hormone therapy and risk of breast cancer detected at screening and between mammographic screens. Int J Cancer 118:3112–3117CrossRefPubMed

28.

Loman N, Johannsson O, Kristoffersson U, Olsson H, Borg A (2001) Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. JNCI 93(16):1215–1223PubMed

29.

Olsen AH, Bihrmann K, Jensen MB, Vejborg I, Lynge E (2009) Breast density and outcome of mammography screening: a cohort study. Br J Cancer 100(7):1205–1208CrossRefPubMed

30.

Kavanaugh A, Byrnes GB, Nickson C et al (2008) Using mammographic density to improve breast cancer outcomes. CEBP 17(10):2818–2824

31.

McTiernan A, Martin CF, Peck JD et al (2005) Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women’s Health Initiative randomized trial. J Natl Cancer Inst 97(18):1366–1376CrossRefPubMed

32.

Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principle results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333CrossRefPubMed

33.

Chlebowski RT, Hendrix SL, Langer RD et al (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA 289(24):3243–3253CrossRefPubMed

34.

Nicholson BT, LoRusso AP, Smolkin M, Bovbjerg VE, Petroni GR, Harvey JA (2006) Accuracy of assigned BI-RADS breast density category definitions. Acad Radiol 13(9):1143–1149CrossRefPubMed

35.

Taylor R, Supramaniam R, Rickard M, Estoesta J, Moreira C (2002) Interval breast cancers in New South Wales, Australia, and comparisons with trials and other mammographic screening programmes. J Med Screen 9(1):20–25CrossRefPubMed

36.

Moskowitz M (1986) Breast cancer: age-specific growth rates and screening strategies. Radiology 161:37–41PubMed

37.

Tabar L, Chen HH, Fagerberg G, Duffy SW, Smith TC (1997) Recent results from the Swedish Two-County Trial: the effects of age, histologic type, and mode of detection on the efficacy of breast cancer screening. J Natl Cancer Inst Monogr 22:43–47PubMed

38.

Duffy SW, Day NE, Tabar L et al (1997) Markov models of tumor progression: some age-specific results. J Natl Cancer Inst Monogr 22:93–97PubMed

39.

Tabar L, Fagerberg G, Duffy SW (1995) Efficacy of breast cancer screening by age. New results from the Swedish Two-County Trial. Cancer 75(10):2507–2517CrossRefPubMed

40.

Buist DS, Porter PL, Lehman C, Taplin SH, White E (2004) Factors contributing to mammography failure in women aged 40–49. J Natl Cancer Inst 96(19):1432–1440CrossRefPubMed

41.

Nickson C, Kavanagh AM (2009) Tumor size at detection according to different measures of mammographic breast density. J Med Screen 16(3):140–146CrossRefPubMed

42.

Roubidoux MA, Bailey JE, Wray LA, Helvie MA (2004) Invasive cancers detected after breast cancer screening yielded a negative result: relationship of mammographic density to tumor prognostic factors. Radiology 230(1):42–48CrossRefPubMed

43.

Guo YP, Martin LJ, Janna W, Banerjee D (2001) Growth factors and stromal matrix proteins associated with mammographic densities. CEBP 10:243–248

44.

Gill KS, Yankaskas BC (2004) Screening mammography performance and cancer detection among black women and white women in community practice. Cancer 100(1):139–148CrossRefPubMed

45.

Rosenberg RD, Lando JF, Hunt WC et al (1996) The New Mexico Mammography Project Screening mammography performance in Albuquerque, New Mexico, 1991 to 1993. Cancer 78(8):1731–1739CrossRefPubMed

46.

Poplack SP, Tosteson AN, Grove MR, Wells WA, Carney PA (2000) Mammography in 53, 803 women from the New Hampshire mammography network. Radiology 217(3):832–840PubMed

47.

Gower-Thomas K, Fielder H, Branston L, Greening S, Beer H, Rogers C (2002) Reviewing interval cancers: Time well spent? Clin Radiol 57:384–388CrossRefPubMed

48.

McCann J, Britton PD, Warren RML, Hunnam G (2001) Radiological peer review of interval cancers in the East Anglian breast screening programme: what are we missing? Jr Med Screen 8(2):77–83CrossRef

49.

Klemi PJ, Toikkanen S, Rasanen O, Parvinen I, Joensuu H (1997) Mammography screening interval and the frequency of interval cancers in a population-based screening. Br Jr Cancer 75(5):762–766

50.

Raja MA, Hubbard A, Salman AR (2001) Interval breast cancer: is it a different type of breast cancer? Breast 10(2):100–108CrossRefPubMed

Titel: Complementary approaches to assessing risk factors for interval breast cancer
verfasst von: Jan T. Lowery
Tim Byers
John E. Hokanson
John Kittelson
John Lewin
Betsy Risendal
Meenakshi Singh
Judy Mouchawar
Publikationsdatum: 01.01.2011
Verlag: Springer Netherlands
Erschienen in: Cancer Causes & Control / Ausgabe 1/2011
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-010-9663-x

Neu im Fachgebiet Onkologie

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Brustkrebs-Prävention wird neu gedacht

04.06.2024 ASCO 2024 Kongressbericht

Zurzeit untersuchen Forschende verschiedene neue Ansätze zur Prävention von Brustkrebs bei Personen mit hohem Risiko. Darunter Denosumab, die prophylaktische Bestrahlung der Brust – und Impfungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2011

Dietary methyl donors, methyl metabolizing enzymes, and epigenetic regulators: diet–gene interactions and promoter CpG island hypermethylation in colorectal cancer

Is it time to change the stereotype of cancer: the expert view

The roles of ultraviolet-B irradiance, vitamin D, apolipoprotein E ε4, and diet in the risk of prostate cancer

Vitamin D, calcium, and retinol intake, and pancreatic cancer in a population-based case–control study in the San Francisco Bay area